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collapse. In fact, in the in vitro study in dogs in which 
ICAC for human use was applied, 2we confirmed that a 
flow rate of 2 L/rain was obtained at an intracirculatory 
negative pressure of 100 to 140 mm Hg at the proximal 
portion of the centrifugal pump. 
The main point of our article~is to show by experiments 
in dogs that despite incomplete decompression ( ot the 
total decompression of the left ventricle reported previ- 
ously by others 4) and also by left ventricular drainage, the 
peripheral circulation can be maintained and the left 
ventricle supported by adding electrocardiographically 
gated pulsatility. Thus pulsatility compensates for the 
limited maximal flow rate, which is the essential problem 
associated with our catheter. If the experimental results 3
are applied strictly and quantitively to the clinical situa- 
tion, we have to admit the necessity of an ICAC maximal 
flow rate of 3 L/min, taking into consideration the safety 
margin pointed out by Dr. De Paulis. However, we have 
used the ICAC catheter for left ventricular bypass in two 
patients with profound left ventricular failure causedby 
ischemic heart disease (reference No. 5 and unpublished 
data), and the maximum flow rate of 2 L/min was obtained 
in both cases, similar to in vivo and in vitro experiments. 
With this flow rate, peripheral circulation could be main- 
tained; moreover, echocardiographic f ndings revealed 
improvement in the left ventricular performance of the 
ischemic heart itself, and changes in serum free hemoglo- 
bin levels were within the acceptable range. 
Because we have applied our catheter in only two cases 
so far, we cannot yet draw a definite conclusion as to 
whether the maximal flow rate of our ICAC for clinical 
use is acceptable. We want to investigate further the 
efficacy of the left ventricular bypass method by ICAC in 
a number of cases. 
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Evaluating the impact of magnetic resonance 
imaging on patients with operable non-small-cell 
lung cancer and unilateral adrenal masses: 
Importance of appropriate technique 
To the Editor: 
I appreciate the recent effort by Burt and associates a to 
address the ability of magnetic resonance imaging (MRI) 
to distinguish between benign and malignant adrenal 
masses in patients with non-small-cell lung cancer. Unfor- 
tunately, their methods preclude adequate valuation. 
Butt and associates do not describe their MRI tech- 
nique adequately. A simple label of "T2-weighted" is not 
sufficient. A wide variety of parameters, uch as repetition 
time (TR) and echo time (TE), can affect image contrast 
on "T2-weighted" images. The limitations of this study, 
however, extend beyond this omission. 
In their introduction, the authors efer to early studies 
using midfield (0.35 to 0.5 T) MRI instruments in which 
adrenal adenomas were found to have signal intensity 
similar to that of liver. The authors then refer to two more 
recent studies using higher field strength instruments (1.5 
T) which "tried to develop MRI criteria to predict 
whether an adrenal mass is benign or malignant. ''2' 3 In 
particular, these authors found that at 1.5 T, the liver is 
not a suitable standard for visual comparison to adrenal 
glands and that T2 ratios were far more useful. Unfortu- 
nately, Burt and colleagues have attempted to discrimi- 
nate between benign and malignant adrenal masses at 1.5 
T using the already discredited technique of visual com- 
parison to liver. 
Simple comparison of signal intensities on T2-weighted 
images cannot distinguish accurately between adrenal 
adenomas and metastases because lipid (abundant in 
adrenal adenomas) and neoplastic tissue both have high 
signal intensity on most T2-weighted images. A more 
direct method for distinguishing between benign and 
malignant adrenal masses, based on specific histologic 
differences between these entities, was suggested by Le- 
roy-Willig and coworkers 4 in 1987. In this in vitro pilot 
study, these authors successfully used chemical-shift 
(spectroscopic) magnetic resonance techniques for reli- 
able identification of small quantities of lipid within 
benign adrenal masses. In a subsequent study in 1989, 
they 5confirmed these principles in vivo using techniques 
not available at most MRI centers. Subsequently in 1992, 
my colleagues and 16 published our results with chemical- 
shift MRI techniques that were commercially available on 
many MRI systems, including the system as used by Burt 
and associates. This chemical-shift MRI technique has 
subsequently been confirmed by other authors as highly 
accurate for distinguishing benign from malignant adrenal 
masses. 7 Thus we currently recommend chemical-shift 
MRI as a reliable and practical method for distinguishing 
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between benign a d malignant adrenal masses. Burr and 
coworkers in fact refer to our 1992 article and acknowl- 
edge that chemical-shift MRI might be more effective 
than the methods they used. They did not, as they state, 
use the "best currently available MRI scanning tech- 
niques" for their 1994 publication. 
I hope that Burt and associates and other thoracic and 
cardiovascular surgeons maintain their interest in the 
potential impact of MRI on presurgical diagnosis. Well- 
designed studies on this subject would be of benefit o the 
surgical and radiologic literature alike. 
Donald G. Mitchell, MD 
Professor of Radiology 
Thomas Jefferson University Hospital 
Jefferson Medical College 
132 South lOth St. 
196 Main Building 
Philadelphia, PA 19107 
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Reply to the Editor: 
In response to Dr. Donald G. Mitchell's letter to the 
Editor, we have the following comments. We thank Dr. 
Mitchell for his comments and criticisms. Although mag- 
netic resonance imaging (MRI) methods are currently 
being investigated that possibly could lead to better 
discrimination of adrenal masses as being benign or 
metastatic n non-small-cell lung cancer, Dr. Mitchell did 
not take into account the time it takes for a scientific study 
to come to full publication. The inception of the study was 
in February of 1990, and it was approved by our institu- 
tional review board in April of 1990. The accrual of the 
patients reported in our study began in August of 1990 
and was completed in October of 1992. An abstract of our 
study was submitted to The American Association for 
Thoracic Surgery on November 11, 1993, and the paper 
was presented at the Seventy-third Annual Meeting in 
April of 1993. A manuscript was submitted at this meet- 
ing. This manuscript was accepted August 20, 1993, and 
published in the February 1994 issue of THE JOUm~AL Or 
THORACIC AND CARDIOVASCULAR SURGERY. Dr. Mitchell 
published his technique of chemical shift MRI in the 
November 1992 issue of Radiology, after the completion of 
our study. 
Although newer techniques are being developed in 
MRI to differentiate benign from malignant adrenal 
masses, few studies have histologic documentation f all 
patients reported. Therefore, although our study used the 
MRI techniques available during the period of the study, 
the point is still valid that the gold standard for determin- 
ing the cause of adrenal masses is by cytopathologic or
histopathologic study. We too are currently evaluating 
chemical-shift MRI and other newer MRI techniques, but 
we remain convinced that histologic examination is the 
gold standard by which to compare any new MRI tech- 
nique. 
Michael Burt, MD, PhD a 
Robert Heelan, MD b 
Department of Surgery a 
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Airway complications after lung transplantation: 
Is there a left-sided predilection? 
To the Editor: 
We read with interest he article by Griffith and asso- 
ciates 1 that was published in this JOURNAL. They have 
clearly shown that most complications of airway anasto- 
moses after lung transplantation can be avoided by the 
refinement of surgical techniques (Table I, J THOgAC 
CARDIOVASC SURG 1994;107:746). Although the etiology 
of impaired bronchial healing after lung transplantation is 
multifactorial, bronchial ischemia seems to be the primary 
cause. 2 In this series all seven patients with severe bron- 
chial stenoses after bilateral lung transplantation had 
stenotic lesions of the left bronchus (three had bilateral 
stenoses). These patients were treated with endobronchial 
stents. Two patients had bronchial stenosis necessitating 
stenting after single left lung transplantations; by contrast, 
no bronchial stenoses occurred after single right lung 
transplantation (Table II, J THORAC CARDIOVASC SUR~ 
1994;107:746). Colt and associates 3 also have reported 
that all ten patients in whom stenosis developed after 
double lung transplantation demonstrated abnormalities 
at the level of the left main bronchial anastomosis (three 
had bilateral stenoses). 
